Cliquez ici pour le voir en ligne

‍CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC)
Glenwood Goss
13.09.2024
14:00 - 15:30

Bilbao Auditorium - Hall 2

>> PROFFERED PAPER SESSION  

‍Encorafenib plus binimetinib in patients with previously untreated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC): An open-label, multicenter phase II trial (IFCT-1904 ENCO-BRAF)

David Planchard 
14.09.2024

11.25 - 11.30

Santander Auditorium - Hall 5

>> MINI ORAL SESSION 

‍Durvalumab in treatment-naive, stage IV non-small cell lung cancer (NSCLC) patients, with ECOG performance status (PS) 2-3 and high PD-L1 tumour expression: Results of IFCT-1802 SAVIMMUNE phase II trial
Valérie Gounant

14.09.2024

>> POSTER SESSION 

Se désinscrire